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ABSTRACT
Urothelial cell carcinoma of the bladder (UCC) is a common disease often 
characterized by FGFR3 dysregulation. Whilst upregulation of this oncogene occurs 
most frequently in low-grade non-invasive tumors, recent data reveal increased 
FGFR3 expression characterizes a common sub-type of invasive UCC sharing molecular 
similarities with breast cancer. These similarities include upregulation of the FOXA1 
transcription factor and reduced expression of microRNAs-99a/100. We have 
previously identified direct regulation of FGFR3 by these two microRNAs and now 
search for further targets. Using a microarray meta-database we find potential FOXA1 
regulation by microRNAs-99a/100. We confirm direct targeting of the FOXA1 3’UTR 
by microRNAs-99a/100 and also potential indirect regulation through microRNA-485-
5p/SOX5/JUN-D/FOXL1 and microRNA-486/FOXO1a. In 292 benign and malignant 
urothelial samples, we find an inverse correlation between the expression of FOXA1 
and microRNAs-99a/100 (r=-0.33 to -0.43, p<0.05). As for FGFR3 in UCC, tumors 
with high FOXA1 expression have lower rates of progression than those with low 
expression (Log rank p=0.009). Using global gene expression and CpG methylation 
profiling we find genotypic consequences of FOXA1 upregulation in UCC. Genetic 
changes are associated with regional hypomethylation, occur near FOXA1 binding 
sites, and mirror gene expression changes previously reported in FGFR3 mutant-UCC. 
These include gene silencing through aberrant hypermethylation (e.g. IGFBP3) and 
affect genes characterizing breast cancer sub-types (e.g. ERBB2). In conclusion, we 
have identified microRNAs-99a/100 mediate a direct relationship between FGFR3 and 
FOXA1 and potentially facilitate cross talk between these pathways in UCC.
INTRODUCTION
Urothelial carcinoma of the bladder (UCC) is 
the fourth commonest male malignancy [1]. Despite 
its high prevalence and the cost of managing affected 
patients, there have been few advances in the treatment 
of this disease since the introduction of cisplatin based 
regimens [2, 3]. Clinical and molecular data suggest UCC 
is characterised by two distinct phenotypes with low and 
high-grade differentiation [4, 5]. Whilst the former has an 
excellent prognosis [6], high-grade tumors are aggressive 
cancers that progress to invasion, metastases and death 
[7]. Recent profiling reports have revealed invasive high-
grade UCC can be clustered according to genes reflecting 
FGFR3 status (including papillary histology and FGFR3 
related microRNAs), those seen in luminal breast cancer, 
and epithelial lineage and stem/progenitor cytokeratins 
(including a proportion of tumors with squamous 
histology) [8]. This clustering can reflect basal-like and 
luminal compartments in breast cancer, and may result in 
different sensitivities to cisplatin based chemotherapy [9], 
[10].
These data underlie the importance of FGFR3 
in UCC biology. Whilst mutation of this oncogene 
occurs most commonly in low-grade non-invasive 
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UCC [11], FGFR3 upregulation characterises the large 
chemosensitive sub-group of invasive cancers [10]. We 
were the first group to report FGFR3 upregulation in UCC 
through loss of microRNA-99a/100 expression (miRs-
99a/100) [12]. We identified this appeared before FGFR3 
mutation and may explain the high proportion of invasive 
UCC with upregulated wild type FGFR3 [8]. Importantly, 
the FGFR3 cluster of invasive UCC are also characterised 
by loss of expression of miRs-99a/100. MicroRNAs 
(miRs) are short non-coding RNA molecules that post-
transcriptionally modulate protein expression [13]. Mature 
miRs are directed to mRNAs with a complementary 
seed sequence to nucleotides 1-8 of their 5’ structure. 
Modulation of protein expression appears proportional to 
the extent of complementation, the context, the frequency 
and proximity, and the evolutionary conservation of the 
seed sequence. As each miR may target many mRNAs, we 
hypothesized that miRs-99a/100 modulate the expression 
of other mRNAs important for UCC biology. Here we 
report a search for and validation of potential candidates.
RESULTS
Identification of potential targets for miRs-
99a/100
We extracted mRNA expression profiles from 7 
microarray datasets [14-18] [19] [20] defining genes 
upregulated in n=958 low grade, superficial or non-muscle 
invasive UCC (n=12 Oncomine concepts, Supplementary 
table 1) when compared to either invasive (n=446) tumors 
or normal urothelial (n=135) samples. We selected the 
top 10% of upregulated genes (4,935 unique genes) and 
identified 20 that were predicted to be targets of miRs-
99a/100 (from a total of 52 predicted targets). Upregulated 
genes appeared enriched for miR-99a/100 targets, when 
compared to the entire genome (20/4,935 vs 52/32,000, 
χ2=8.2, p<0.001). We ranked genes according to frequency 
of detection in the microarray comparisons (table 1). The 
commonest detected target was FGFR3 (found in 8/12 
concepts), followed by the transcription factors FOXA1 
and HOXA1 (in 6/12 and 3/12 concepts, respectively). 
We correlated expression profiles for miRs-99a/100 
with these predicted targets using RNA profiles in the 72 
samples from cohort 1 (table 2) and identified significant 
inverse correlations for FGFR3 (r=-0.48 to -0.52, p<0.01) 
and FOXA1 (r=-0.33 to -0.43, p<0.05). Non-significant 
negative correlations were seen for HOXA1.
Targeting of FOXA1 by miRs-99a/100
To explore targeting of FOXA1 and HOXA1 by 
miRs-99a/100, we examined protein expression in NHU 
cells following microRNA knockdown. For comparison 
we included FGFR3, phosphorylated-ERK 1/2 (as a 
marker of FGFR3 signaling pathway activity) and IGF1R 
(also potential target). Upregulation of FOXA1 (2.9 to 
3.1 fold (±st. dev. 0.23 to 0.32)) and FGFR3 (1.5 to 2.1 
fold (±0.15 to 0.23)) and ERK1/2 phosphorylation (1.3 
to 2.5 fold (±0.1 to 0.4)) was seen following knockdown 
(figure 1a). In contrast, no change was seen for IGF1R 
and HOXA1. To investigate direct targeting of the FOXA1 
3’ UTR we synthesized a luciferase reporter construct 
incorporating the miR-99a/100 seed sequence from 
FOXA1. We observed increases in luciferase fluorescence 
with anti-miRs to miR-99a (1.4 fold (±0.2)) and miR-100 
(1.5 fold (±0.21), figure 1b). 
Whilst direct targeting of the FOXA1 3’ UTR may 
occur through miRs-99a/100, we wondered whether a 
further indirect pathway may contribute to the 2-3 fold 
rise in protein expression seen. We investigated the 
potential for microRNA networks within a tumor [21]. 
Table 1: Predicted targets of microRNA-99a/100 found 
with increased expression in low grade or non-invasive 
in Urothelial carcinoma of the bladder. The frequency 
of detection (from 12 Oncomine concepts) is shown, 
together with the Pearson’s correlation coefficient to the 
expression of miRs-99a/100 in 72 urothelial samples
 Freq. in 
Oncomine 
concepts
Pearson's correlation of miR-
mRNA expression
Gene miR-99a miR-100
FGFR3 8 -0.48** -0.52**
FOXA1 6 -0.43** -0.33*
HOXA1 3 -0.22 -0.16
BMPR2 2 0.03 0.10
ICMT 2 0.07 0.05
MTMR3 2 0.04 0.05
OGT 2 0.04 0.05
ZBTB7A 2 -0.11 -0.05
ADCY1 1 -0.09 0.12
C4orf16 1 0.32 0.14
EIF2C2 1 -0.18 -0.12
FRAP1 1 -0.01 0.04
HS3ST3B1 1 0.08 0.08
IGF1R 1 -0.06 -0.07
NXF1 1 0.12 0.07
PI15 1 0.05 0.10
PPP1CB 1 0.04 0.13
SMARCA5 1 0.07 0.02
SMARCD1 1 0.18 0.04
ZZEF1 1 0.20 0.03
* Significance p<0.05
** Significance p<0.01
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We performed TLDA multiplex qrtPCR in triplicate on 
the NHU cells with anti-miRs to 99a/100 and a scrambled 
control. When normalized to this control, concordant 
reduced expression (<0.5 fold) was seen for 9 miRs (7 
shared between miRs-99a/100) and increased expression 
(>2 fold) for 63 miRs (supplementary figure 1). We 
focused upon the 7 miRs with reduced expression for 
both miRs-99a/100, hypothesizing their loss could lead to 
upregulation of FOXA1 promoting factors. The expression 
of each miR was closely correlated (Pearson’s Coefficient 
r=0.43 to 0.74, p=8.0x10-14 to 0.08, table 3) with miRs-
99a/100 in the 72 urothelial samples from cohort 1. 
Predicted mRNA targets of these 7 miRs (obtained 
from TargetScan) included 14 transcription factors with 
binding sites within the FOXA1 promoter, e.g. miR-485-
5p predicted to target SOX5, JUN-D and FOXL1, and 
miR-486 proven to regulate FOXO1a [22]. As such, loss 
of expression of these miRs may lead to upregulation of 
these transcription factors and increased FOXA1. 
FOXA1 and FGFR3 expression in bladder cancer
Whilst recent data report upregulation of both 
FGFR3 and FOXA1 characterize the papillary (luminal 
breast cancer-like) molecular subtype of invasive UCC 
[8] [10], these reports did not include low-grade tumors. 
To examine expression throughout the UCC spectrum 
and to compare profiles with outcome, we measured 
mRNA using QrtPCR in 220 urothelial samples (cohort 
2). For both mRNAs, highest expression was seen in non-
invasive pTa and low-grade tumors (ANOVA p<0.02, 
Supplementary figure 2)). Upregulation of both FGFR3 
and FOXA1 (when dichotomized around the mean) 
was seen in 69% of low-grade, in 47% of high-grade 
NMI and in 38% of muscle invasive cancers with high 
expression of either (figure 1c, χ2=18.0, p<0.001). Tumors 
with high expression had lower rates of progression to 
more advanced disease, when compared to those with 
Table 2: Description of the patient samples used to investigate miRs-99a/100 targeting of mRNAs in 
bladder cancer. The first cohort was used to investigate correlations between potential target genes and 
microRNA expression. The second cohort was used to explore the role of the predicted targets across the 
UCC spectrum 
  Cohort 1 Cohort 2
  n % n %
Tissue UCC 52 72.2% 207 94.1%
Normal (UCC case) 10 13.9% 7 3.2%
Normal (non-UCC) 10 13.9% 6 2.7%
Gender Male 40 76.9% 161 73.2%
Female 12 23.1% 59 26.8%
Age Mean 72.3 yrs 71.9 yrs
Range 46-90 yrs 36-93 yrs
Phenotype Low Grade NMI 22 42.3% 60 27.3%
High Grade NMI 12 23.1% 56 25.5%
Invasive 18 34.6% 81 36.8%
Not known 8 3.6%
Stage pTa 25 48.1% 74 33.6%
pTis 2 3.8% 9 4.1%
pT1 7 13.5% 35 15.9%
pT2-4 18 34.6% 81 36.8%
Not known 8 3.6%
Recurrence Yes 27 51.9% 49 22.3%
No 25 48.1% 149 67.7%
Progression Yes 18 34.6% 61 27.7%
No 34 65.4% 137 62.3%
Follow up Mean 35.6 months 32.4 months
Range 0-93 months 0.6-111 months
Total  72 100% 220 100%
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low expression (figure 1d). This difference reached 
significance for FOXA1 (Log rank p=0.009, Bonferroni 
corrected) but not FGFR3 (p=0.08). Sub-group analysis 
revealed that this difference in progression free survival 
was only apparent in non-invasive cancers (supplementary 
figure 3) and in low grade tumors (data not shown, Log 
rank values for FOXA1; low grade p=0.002, high grade 3 
p=0.24. Log rank values for FGFR3; low grade 1 p=0.003, 
high grade 3 p=0.29).
Molecular events of FOXA1 upregulation in 
Bladder Cancer
Having identified high FOXA1 and high FGFR3 
expression are correlated in a cohort of UCC and partially 
regulated through miRs-99a/100, we wondered about the 
molecular consequences of FOXA1 upregulation in UCC. 
For analysis, we transfected EJ/T24 cells (as they have 
low FOXA1 expression, have wild type FGFR3 and are 
not dependent upon FGF signaling) with FOXA1 or the 
empty plasmid (control)(supplementary figure 4) [23]. 
We analyzed whole genome mRNA expression and CpG 
methylation, as reports show that FOXA1 recruitment 
is associated with DNA demethylation and changes in 
chromatin conformation [24-26] [27]. Microarray data 
were filtered for probes concordant between duplicates 
and experimental replicates, before matching between 
platforms and normalizing to control (cells transfected 
with the empty plasmid). Our final dataset included 
12,939 genes with 162,338 matching CpG probes across 
the promoter region (n=51,112), inside exon 1 and around 
transcription start sites (n=105,133), and downstream 
from the gene (n=6,093) (dataset is available at http://
www.sheffield.ac.uk/oncology/units/urology/data). As 
expected, we observed increases in gene expression 
with the density of CpG hypomethylation and reductions 
in expression with hypermethylation (T test p<0.001, 
supplementary figure 5) in FOXA1 transfected cells [28]. 
These associations were closest for CpG probes within the 
gene promoter and around the transcription start site/exon 
1 (annotated as inside the gene), when compared to probes 
downstream from the gene.
FOXA1 transfection produced upregulation of 
5,455/12,939 (42%) transcripts including 1,650 (13%) 
with more than 1.2 fold increase (supplementary figure 
Table 3: Correlation of microRNAs with loss of expression following miRs-99a/100 knock-down. (a). Expression is 
shown (as fold change) for each miR in NHU cells transfected with anti-miRs to miRs-99a/100, normalised to scrambled 
RNA control. For each, the correlation of expression is also shown in 72 urothelial samples (from cohort 1). In (b). we show 
predicted targeting by these microRNAs of transcription factors with binding sites within the FOXA1 promoter. For example, 
miR-485-5p is predicted to target 3 transcription factors. Targeting of FOXO1a by miR-486 has been reported [22]
a). Reciprocal loss of microRNA expression following miRs-99a/100 knock-down
 miR-485-5p miR-500a miR-486 let-7e miR-657 miR-133b miR-139-5p
Fold change (with anti miR-100) 0.001 0.01 0.01 0.04 0.04 0.001 0.05
Fold change (with anti miR-99a) 0.001 0.01 0.06 0.27 0.33 0.99 0.05
Correlation with miR-100 (Pearson, R) 0.71 0.52 0.43 0.56 0.26 0.65 0.68
p value 2.01E-09 6.20E-06 4.98E-05 5.14E-08 9.52E-02 4.03E-11 2.38E-11
Correlation with miR-99a (Pearson, R) 0.68 0.57 0.46 0.6 0.27 0.65 0.74
p value 1.61E-08 7.60E-07 1.23E-05 4.61E-09 8.87E-02 4.12E-11 8.00E-14
b). Transcription factors within the FOXA1 promoter
 miR-485-5p miR-500a miR-486 let-7e miR-657 miR-133b miR-139-5p
AHR  1      
AML1A 1
BACH1 1
FOXL1 1
FOXO1a 1 1
HOXA9 1 1 1
JunD 1
SOX5 1 1
Sp1     1 1  
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5), when compared to controls. Differences in expression 
reached significance (FDR <5%) in 50 genes, including 
14 up and 36 down-regulated mRNAs. These were 
involved in the negative regulation of signal transduction, 
chromatin alterations and nucleosome assembly, DNA 
methylation, DNA binding and mutagenesis repair and 
metabolic regulation (p<0.05, supplementary table 2). 
Identified members included those previously shown to 
be aberrantly silenced through DNA hypermethyaltion 
in UCC, e.g. IGFBP3 [29], and those found to charactize 
breast cancer sub-types (e.g. ERBB2) [10]. MEDIP-
Chip identified increases in CpG hypomethylation for 
32/111(29%) promoter, 32/96 (33%) inside and 10/13 
(77%) downstream probes (chi sq. p=0.002) within 5 of 
the 14 upregulated genes. Contrastingly, reduced mRNA 
expression was seen in 7,484 (58%) genes following 
FOXA1 transfection, including 567 (4%) with less than 
0.8 fold change. Increases in aberrant hypermethylation 
were seen at CpG loci in 1,708 (23%) and 134 (24%) of 
these down regulated genes, respectively. Motallebipour 
et al. mapped FOXA1 binding sites in the hepatocellular 
carcinoma cell line HepG2 [30]. We annotated our 
Figure 1: Regulation of FOXA1 expression by microRNAs-99a/100 in bladder cancer. (a). Western blotting for protein 
expression reveals upregulation of FGFR3, phosphorylation of ERK1/2 and FOXA1 following transfection of NHU cells with anti-miRs to 
miRs-99a/100 but not the scrambled RNA control. Image densitometry reveals 3-fold increases in expression for FOXA1 with anti-miRs-
99a/100. (b). A reporter construct assay reveals 1.3/1.4 fold increases in luciferase expression in NHU cells treated with anti-miRs-99a/100, 
when normalized to the scrambled control. Expression profiling using QrtPCR in 220 benign and malignant urothelial samples revealed (c). 
overlap of upregulation for FOXA1 and FGFR3 in UCC, which is greatest in low-grade NMI cancers, and (d). lower rates of progression 
to more advanced disease for tumors with high FGFR3 and high FOXA1 when compared to those with low expression (the difference in 
greatest in low stage and low tumors (supplementary figure 3)). (e). Genes with upregulation following FOXA1 transfection in T24/EJ 
cells are located closer to known FOXA1 binding sites (in HepG2 cells) than those with no change in expression or those with reduced 
expression (down regulation).
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dataset with these loci and compared proximity for 
these 50 significantly altered genes. Genes with 
increased expression following FOXA1 transfection 
were significantly closer to FOXA1 binding sites (mean 
217,515bp (95%CI=159,432-275,598)) than those without 
change (1,774,996bp (1,110,313-2,439,680), figure 1e, T 
Test p<0.001). Conversely, those with reduced expression 
following FOXA1 transfection were significantly more 
distant (2,048,425bp (1,015842-3,081,008) than those 
without change (802,277bp (425,626-1,178,928) p=0.008).
Figure 2: Symmetry of genotype between FOXA1 transfected cells, FGFR3 mutant tumors and in sporadic UCC. 
Gene expression changes following FOXA1 transfection in T24/EJ cells share many similarities with those found in FGFR3 mutant 
bladder UCC. In (a). we stratify changes in normalized gene expression following FOXA1 transfection within T24/EJ by those seen in 
FGFR3 mutant UCC. Genes upregulated in FGFR3 mutant tumors (labeled as Increased) have significantly higher expression in FOXA1 
transfected cells than those with no change in FGFR3 mutants. The difference is largest for genes with associated DNA hypomethylation. 
No significant difference is seen for genes with decreased expression or DNA hypermethylation. (b). Area proportional Venn diagrams 
reveal the overlap for genes in FGFR3 mutant UCC and those upregulated following FOXA1 transfection or with increases in DNA 
hypomethylation following FOXA1 transfection (left). Overlap was also seen for genes downregulated in FGFR3 mutant UCC, and 
those down regulated or hypermethylated following FOXA1 transfection. We identified a 156 gene cohort with reciprocal, symmetrical 
expression in FOXA1 transfected cells and FGFR3 mutant UCC and analyzed this in a publically deposited microarray dataset [32]. In (c). 
we plot the fold change of these 156 genes as a ratio for low-grade NMI cancers relative to high-grade NMI cancer (orange triangle) and 
invasive cancers (blue). In (d). we plot the correlation coefficient vales (r) between expression of FGFR3 and FOXA1 in the 256 sporadic 
UCC [32]. The 156 genes in (c) and (d) are ordered according to expected fold changes (bar: green is loss of expression, red is increased 
expression) as seen in FOXA1 transfected cells. Significance of difference in fold change (low grade NMI versus more aggressive cancers) 
is shown as *p<0.05 and **p<0.01.
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FOXA1 gene expression profiles in FGFR3 
mutant and sporadic bladder tumors
Our data report correlated upregulation of FOXA1 
and FGFR3 in UCC, partly through dual regulation 
by miRs-99a/100. Consequently, tumors with aberrant 
FGFR3 or FOXA1 expression may have symmetry of 
genotype. Lindgren et al. reported 380 genes upregulated 
and 468 down regulated in 46 UCC with mutant FGFR3 
compared to 29 wild type controls [31]. We identified 
222 and 325 of these, respectively, in our dataset. When 
compared, genes with upregulation in FGFR3 mutant 
cancers had significantly higher expression in the FOXA1 
transfected cells (average 1.10±0.2 fold change, p<0.001, 
Figure 2a) than those without change. The difference 
was greater when genes with probes enriched for CpG 
hypomethylation were selected (relative fold change 
1.12±0.2, p<0.001). In contrast, no difference in expression 
was seen for genes down regulated in FGFR3 mutant 
cancers in our FOXA1 transfected cells, even if those 
with hypomethylated or hypermethylated probes were 
selected (fold change 1.03±0.17, p=0.08). Comparison 
between the genes altered with FGFR3 mutation, with 
FOXA1 transfection and changes in DNA methylation 
revealed considerable overlap (figure 2c). Genes with 
increased expression in FGFR3 mutant cancers were 
significantly closer to FOXA1 binding sites (433,101bp 
(95%CI=331,878-534,324)) than those without change 
(837,209bp (814,843-859,575) T Test p<0.001). Those 
with reduced expression in FGFR3 mutants were also 
significantly closer (315,103bp (261,634-368,572)) than 
those without change (841,086bp (818,606-863,570), 
p<0.001).
For external validation, we examined the genes with 
symmetrical changes in FGFR3 mutant UCC and FOXA1 
transfected cells (135 up and 170 down regulated) using 
a large microarray dataset of 256 sporadic UCC [32]. 
We identified 295 (97%) members and found significant 
aberrant expression, in the symmetrical manner seen in 
FOXA1 transfected cells and FGFR3 mutant UCC, for 
most gene members (89 (67%) up and 87 (54%) down-
regulated genes, T Test p<0.05, suppl. figure 8a). There 
was significant correlation of expression between FOXA1 
and FGFR3 (r=0.45 (95%CI 0.35-0.55), p<0.001), and 
once again the expression of each was highest in non-
muscle invasive cancers (suppl. figure 8b, Χ2 p<0.01). 
Comparative analysis revealed 156/295 (54%) of these 
genes were significantly differentially expressed between 
low-grade NMI, high-grade NMI or invasive cancers 
(Figure 2c, t test p<0.05) in the manner expected from 
FGFR3 mutant UCC/FOXA1 transfected cells. The 
expression of many genes was significantly correlated with 
FGFR3, FOXA1 or both. In particular, 72 and 62 predicted 
up regulated genes were significantly positively correlated 
to increases in FOXA1 (r=0.12 to 0.82) and FGFR3 
expression (r=0.12 to 0.82, Figure 2d). Conversely, 32 
and 77 predicted down regulated genes were significantly 
negatively correlated with FOXA1 (r=-0.14 to -0.51, 
p<0.05) and FGFR3 (r=-0.12 to -0.66, p<0.05) expression, 
respectively. 
DISCUSSION
Here we report FOXA1 as a regulatory target of 
miRs-99a/100 in UCC. This follows our previous findings 
identifying FGFR3 as a target of miRs-99a/100 [12] and 
supports data revealing these microRNAs discriminate of 
UCC genotype [8]. Our work provides a direct mechanistic 
link between miRs-99a/100, FGFR3 and FOXA1. The 
central role of miRs-99a/100 in this association suggests 
epigenetic events either precede the development of 
tumor genotype or act as a link between these pathways in 
tumors when either event occurs in isolation. For example, 
FGFR3 mutation may lead to increased mRNA expression, 
annealing and sequestration of miRs-99a/100 leading 
to FOXA1 upregulation [33]. There was considerable 
overlap between the genotypes of tumors with FOXA1 
upregulation and FGFR3 mutation. This symmetry 
appears mediated through miRs-99a/100 and FOXA1, 
given the proximity of affected genes to FOXA1 binding 
sites and to changes in DNA hypomethylation, suggesting 
this axis plays a key role in determining genetic events in 
low-grade and papillary-type invasive high-grade UCC. 
Genotype often impacts upon phenotype, and we observed 
tumors with high expression of both FOXA1 and FGFR3 
were most commonly low grade non-invasive and had 
lower rates of progression, when compared to those with 
low expression. Outcome differences were only seen in 
non-invasive cancers, suggesting consequential changes 
subsequent to these genes become more important with 
tumor evolution. 
Our data provide an explanation of previous CpG 
methyl profiling reports. Wolff et al. identified regional 
hypomethylation across 16% of CpG probes in low 
grade UCC, when profiling a large UCC cohort [34]. 
FOXA1 is a transcription factor recruited to enhancers 
that acts to influence chromatin interactions through 
DNA demethylation and H3K4 methylation [24, 27]. The 
role of FOXA1 in malignancy has been best studied in 
endocrine-dependent cancers, where it is known to act as a 
transcriptional co-factor and to modulate hormone receptor 
activity through chromatin and DNA modifications [35]. 
Our findings also reflect those in a previous report 
of FOXA1 in UCC [36], although we make a different 
interpretation. Specifically, we propose microRNA-
mediated upregulation of FOXA1 in papillary type UCC, 
rather than loss of FOXA1 expression in aggressive, 
squamous tumors. Our findings mirror those seen in other 
malignancies, e.g. FOXA1 upregulation confering a good 
prognosis on cancers with high expression [37, 38] and is 
a representative marker of luminal-type cancers [39], and 
are compatible with DeGraff et al. given recent evidence 
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of a dual role for up and down regulation of FOXA1 in 
cancer [40, 41].
In summary, we identify microRNA mediated 
upregulation of both FGFR3 and FOXA1 in UCC. We 
propose this is a determinant of the papillary genotype of 
these cancers and that FOXA1 is a key mediator of this 
evolution.
MATERIALS AND METHODS
In Silico identification of miR-99a/100 targets in 
UCC
To identify potential targets of miRs-99a/100 in low 
grade UCC we created a microarray meta-database from 
publically deposited UCC mRNA expression datasets 
(from www.oncomine.org). We selected datasets in 
which we could identify genes upregulated in low grade, 
superficial or non-muscle invasive UCC, when compared 
to controls and/or high grade or invasive tumors. We 
searched for predicted targets of miRs-99a/100 (obtained 
from TargetScan (Version 4.2, www.targetscan.org) 
and PicTar (http://pictar.mdc-berlin.de)) across this 
meta-database and ranked according to the frequency of 
detection.
Patients and tumours 
To evaluate potential mRNA targets we studied 
292 freshly frozen urothelial samples (Table 1) from two 
cohorts. The first was used to compare the expression of 
miRs-99a/100 and putative mRNA targets. The second 
examined these putative targets in a larger unrelated 
population. UCC were classified using the 2004 WHO/
ISUP criteria and treated according to standard care 
[5, 42]. Histologically normal urothelial samples were 
obtained from patients with UCC (distant to any tumor) 
and disease-free controls (at prostatectomy). We analyzed 
UCC cell lines representing the disease spectrum (RT4, 
RT112 and EJ/T24, respectively, purchased from ATCC) 
and normal non-immortalized human urothelial (NHU) 
cells [43].
RNA extraction, cDNA synthesis and rtPCR
We extracted total RNA using the mirVanaTM kit 
(Ambion, TX) from 10 x 10uM microdissected frozen 
tumor sections (>90% pure cell populations). We 
measured the expression of potential mRNA target using 
quantitative rtPCR (Taqman commercial assays purchased 
from Applied Biosystems, UK). cDNA was made using 
100ug whole RNA, random primers, RT buffer, dNTP 
(100mM), RNase inhibitor and MultiScribe Reverse 
Transcriptase (cDNA Reverse Transcription kit, Applied 
Biosystems, Warrington, UK). Realtime quantified PCR 
with 2 µL cDNA, gene specific primers with FAM-
TAMRA labeled probes, water and 2x Taqman Universal 
PCR MasterMix (Applied Biosystems, Warrington, UK) 
was performed on the ABI 7900HT system according to 
manufacturers guidelines. Relative mRNA quantification 
was determined with respect to the mean of GAPDH and 
β-Actin. We also used quantitative rtPCR to determine 
microRNA concentrations, with reagents specific to 
the mature 23bp sequence, in isolation and using the 
commercial Taqman low density microarray (n=365 miRs, 
as detailed in [12]). Reverse transcription using stem loop 
primers was performed with 50ng small RNA, MultiScribe 
Reverse Transcriptase (Applied Biosystems, Warrington, 
UK), RNase inhibitor, 100nm dNTPs and nuclease free 
water. Quantification with MGB labeled probes specific to 
the reverse transcribed product was performed according 
to the manufacturer’s guidelines (Applied Biosystems, 
Warrington, UK). Relative miR quantification was 
determined with respect to the average of two snoRNAs 
(RNU44 and RNU48) or the mean of the entire TLDA. 
MicroRNA manipulation and Luciferase reporter 
construct
To examine functional implications of miR 
expression, we manipulated expression using specific 
anti-miRs and a scrambled RNA sequence controls 
(Ambion, TX). All experiments were performed in 
triplicate using non-immortalized NHU cells at 70% 
confluence, as detailed [44]. Briefly, each well of a six-
well tissue culture plate was transfected with 100 pmol 
anti-miR using 5 µl siPORT (Life Technologies) in 200 
µl Optimem (Life Technologies). Knockdown of relevant 
miR was confirmed by miR-specific taqman PCR (Applied 
Biosystems) after 48 hours. 
To investigate direct targeting of the FOXA1 
3’UTR we synthesized a Luciferase reporter construct 
(methods detailed [44]). We cloned 800 bases around 
the miR-99a/100 seed sequence in the FOXA1 3’ UTR 
(chr14: 37,129,203 - 37,129,210) into EJ cells and ligated 
into pMIR REPORT (Invitrogen, UK). Dual luciferase 
assays were conducted in a 6 well plate format at 70% 
confluence. Forty-eight hours post transfection, firefly 
and renilla luciferase were quantified sequentially using 
the Dual Luciferase Assay kit (Promega, UK) and 
luminescence was measured using the manufacturers 
recommended luminometer (Promega Glomax). Firefly 
luciferase expression was quantified and normalized to 
Renilla luciferase expression.
Oncotarget6383www.impactjournals.com/oncotarget
FOXA1 transfection
EJ cells were transfected with a pcDNA3 vector 
containing FOXA1 or an empty vector control. 24 µg 
DNA / 90 µl Lipofectamine LTX (Life Technologies) 
was used to transfect each 90mm dish at 70% confluence. 
Experiments were performed in triplicate. A small portion 
(20%) of transfected cells was used to confirm FOXA1 
expression by western blot.
Genome wide profiling of DNA methylation 
Methylated DNA immunoprecipitation and tiling 
CpG island microarrays (Human CpG Island Microarray, 
Agilent, CA) (MeDIP-CHIP) were used to determine 
genome wide methyl-cytosine profiles, as detailed 
elsewhere [28]. Genomic DNA was sonicated and 
incubated with antibodies raised to either 5mC (anti-5-
methylcytidine, Eurogentec, Hampshire, UK) or murine 
IgG (negative control). The antibody-antigen complex was 
captured with magnetic beads conjugated to anti-mouse-
IgG (Santa Cruz Biotechnology), washed, unbound, non-
specific DNA removed, before methylated DNA elution. 
Immunoprecipitated (Cyanine 5-dUTP) and reference 
DNA (Cyanine 3-dUTP) were labeled (Genomic DNA 
Enzymatic Labeling Kit, Agilent), cleaned (Amicon filters, 
Millipore) and quantified. Competitive hybridization 
onto the CpG microarray was performed (ChIP-on-Chip 
Hybridization Kit, Agilent) in a rotating SureHyb chamber 
at 67oC for 40 hours. Washed slides were scanned (High-
Resolution C Scanner, Agilent) and fluorescence obtained 
using Feature Extraction software. The microarray 
contains 244,000 probes that tile through 27,800 CpG 
features at an average of 100bp separation. We identified 
concordant probes within the highest (>80%) and lowest 
quintiles (<20% of Cy-5) fluorescence and defined these 
as enriched for hyper or hypo-methylated, respectively. 
Finally, as each experiment was performed in triplicate, we 
excluded probes without concordance in 2 or 3 replicates.
Whole genome mRNA expression
Whole genome mRNA expression was determined 
by microarray (HG-U133 Plus 2.0, Affymetrix, Cal.) 
[28]. This platform contains 54,000 probesets, including 
33,000 to known coding genes. RNA was prepared using 
the Affymetrix protocol (enzymes from Invitrogen) and 
annealed to an oligo-d(T) primer with a T7 polymerase 
binding site. cDNA was generated using superscript II 
and E. coli DNA ligase and polymerase I. The reaction 
was completed with T4 DNA polymerase and EDTA. 
Amplified cDNA was cleaned, biotin-labeled, fragmented 
and hybridized to the microarray for 16 hours at 45°C 
in a rotating oven at 60rpm. After washing and staining, 
the arrays were scanned (GC3000 scanner) and data 
processed using Gene Chip Operating System software. 
mRNA expression was determined using Microarray 
Analysis Suite 5 (Affymetrix) and defined as expressed 
(perfect match probeset intensity greater than mismatch 
intensity) or absent (mismatch probeset intensity greater 
or equal to perfect match intensity). Expression data were 
exported into Expression console (Affymetrix), RMA log2 
converted and analyzed within Significance Analysis of 
Microarrays [45]. This microarray data is deposited on line 
at GEO datasets (GEO accession number GSE56037).
Protein expression: western blotting
Cells were lysed in RIPA buffer (20m M Tris·HCl, 
135 mM NaCl, 10% glycerol, 1% Igepal, 0.1% SDS, 0.5% 
deoxycholic acid, 2 mM EDTA) containing protease and 
phosphatase inhibitors (Complete EDTA-free protease 
inhibitor cocktail and PhosSTOP phosphatase inhibitor 
cocktail; Roche, Mannheim, Germany), and protein 
content was quantified using the DC-protein assay reagent 
(Bio-Rad, Hercules, CA). Protein lysates (50µg) were 
loaded onto 8% gels, fractionated, and electroblotted 
onto nitrocellulose membranes. After blocking with 5% 
non-fat milk powder and 0.1% Tween, the membranes 
were incubated overnight with the relevant primary 
antibody (listed in supplementary table 3) overnight 
at 4°C, washed, and incubated at room temperature 
for 1h with an appropriate HRP-conjugated secondary 
antibody (1:1000; Cell Signaling Technologies Inc.). . 
The immune complexes were visualized by enhanced 
chemiluminescence (GE Healthcare, Buckinghamshire, 
UK) and quantified using Image J for band densitometry. 
The final values were plotted relative to the negative 
control and normalized to the corresponding Beta-Actin 
value.
Statistical analysis
Relative mRNA and miR concentrations were 
calculated using the median of their respective reference 
molecules (∆Ct = Ct miR – Ct median control) and expression 
fold changes computed using 2-∆∆Ct calculations [46]. 
MiR-mRNA expression was correlated using Pearson’s 
coefficient. RNA expression was compared with 
clinicopathological data using the χ2, T test or Mann 
Whitney U test where appropriate. Disease progression 
was defined when a non-muscle invasive tumor became 
invasive or a muscle invasive tumor developed metastases. 
Progression-specific survival probability following 
tumor resection was analyzed using the Kaplan-Meier 
method and compared with the Log rank test, for which 
significance was adjusted using a Bonferroni correction. 
Patients without progression were censored at last 
reviewed or when they died of other causes. All analyses 
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were two tailed and carried out using SPSS (version 14, 
SPSS Inc).
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